IL6 and breast carcinoma: While serum inflammatory biomarkers may not be an effective means of identifying or monitoring such patients, these findings lend further support to targeting the IL-6/JAK/STAT pathway in some patients with HER2+ breast cancer who harbor the high-risk IL-6 genotype.